Akero Therapeutics (AKRO) is the lead sponsor of 4 active clinical trials listed on ClinicalTrials.gov[3], including 3 Phase 3[1], 1 Phase 2[2].
Trial NCT06215716[4] evaluates Efruxifermin in NASH With Fibrosis with a target enrollment of 1650 participants. Trial NCT06528314[5] evaluates Efruxifermin in NASH - Nonalcoholic Steatohepatitis with a target enrollment of 1150 participants. Trial NCT06161571[6] evaluates Efruxifermin in NASH/MASH with a target enrollment of 700 participants.
No Form 4 insider filings for AKRO were recorded at the SEC in the past 30 days[7].